These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2452890)

  • 1. Enhancement of natural killer activity in human peripheral blood by flavone acetic acid.
    Urba WJ; Longo DL; Lombardo FA; Weiss RB
    J Natl Cancer Inst; 1988 Jun; 80(7):521-5. PubMed ID: 2452890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological effects of flavone acetic acid.
    Triozzi PL; Rinehart JJ; Malspeis L; Young DC; Grever MR
    Cancer Res; 1990 Oct; 50(20):6483-5. PubMed ID: 2208107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512).
    Ching LM; Baguley BC
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1047-50. PubMed ID: 3665989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.
    Futami H; Hornung RL; Back TT; Bull R; Gruys E; Wiltrout RH
    Cancer Res; 1990 Dec; 50(24):7926-31. PubMed ID: 2253233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta.
    Hornung RL; Young HA; Urba WJ; Wiltrout RH
    J Natl Cancer Inst; 1988 Oct; 80(15):1226-31. PubMed ID: 3418728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
    J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes.
    Futami H; Eader LA; Komschlies KL; Bull R; Gruys ME; Ortaldo JR; Young HA; Wiltrout RH
    Cancer Res; 1991 Dec; 51(24):6596-602. PubMed ID: 1742732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of interferon and tumour necrosis factor by cloned human natural cytotoxic lymphocytes and T cells.
    Christmas SE; Meager A; Moore M
    Clin Exp Immunol; 1987 Aug; 69(2):441-50. PubMed ID: 2443292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of cord blood and adult lymphocytes: interleukin-2 and interferon production, natural killer cell activity, and lymphocyte populations.
    Kibler R; Hicks MJ; Wright AL; Taussig LM
    Diagn Immunol; 1986; 4(4):201-8. PubMed ID: 2428555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium modulates mitogen induced natural killer activity and interferon production.
    Sharma SD
    J Immunopharmacol; 1982-1983; 4(4):303-13. PubMed ID: 6192175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullasin enhances human natural killer cell activity by a mechanism other than the induction of interferons or interleukin-2.
    Aoki Y; Fukuchi K
    Jpn J Cancer Res; 1987 Jan; 78(1):68-73. PubMed ID: 2434455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro production of different interferon types by cloned human NK cells.
    Nocera A; Melioli G; Merli A; Santoro F; Zicca A
    Clin Exp Immunol; 1985 May; 60(2):274-84. PubMed ID: 2408801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer.
    Mace KF; Hornung RL; Wiltrout RH; Young HA
    Cancer Res; 1990 Mar; 50(6):1742-7. PubMed ID: 1689611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cytotoxic factor induction by K562 cells in patients with advanced cancer: correlation with production of interferon.
    Steinhauer EH; Doyle AT; Reed J; Kadish AS
    J Natl Cancer Inst; 1985 Dec; 75(6):1017-23. PubMed ID: 2415742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of resting human peripheral blood natural killer cells to interleukin 2.
    Trinchieri G; Matsumoto-Kobayashi M; Clark SC; Seehra J; London L; Perussia B
    J Exp Med; 1984 Oct; 160(4):1147-69. PubMed ID: 6434688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoferon (AM3) enhances the activities of early-type interferon inducers and natural killer cells.
    Moya P; Baixeras E; Barasoain I; Rojo JM; Ronda E; Alonso ML; Portolés A
    Immunopharmacol Immunotoxicol; 1987; 9(2-3):243-56. PubMed ID: 2449486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
    Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.